Thomas Chi, MD
Ophthalmology · Medina, OHNPI 1851341846
Payments from drug & device makers
Across 114 payments — averaging $43.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Glaukos Corporation$1K
- AbbVie$812
- NEW World Medical,inc.$476
- Johnson & Johnson Surgical Vision, Inc.$222
- Ivantis, Inc$220
- plus $869 from 15 others
What the payments were for
- Consulting fees$55011%
- Speaking & faculty fees$180%
- Travel & lodging$120%
- Food & beverage$4,33788%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 39 | $1,256 |
| Glaukos Corporation | 5 | $1,062 |
| AbbVie(2 entities) | 18 | $812 |
| NEW World Medical,inc. | 10 | $476 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $222 |
| Ivantis, Inc | 3 | $220 |
| Biotissue Holdings Inc. | 2 | $216 |
| Aerie Pharmaceuticals, Inc. | 4 | $172 |
| Sun Pharmaceutical Industries Inc. | 6 | $113 |
| Rayner Intraocular Lenses Limited | 2 | $46 |
| Kala Pharmaceuticals, Inc. | 3 | $43 |
| Omeros Corporation | 3 | $42 |
| ABB Con-cise Optical Group LLC | 1 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| Sight Sciences, Inc. | 1 | $30 |
| Iridex Corporation | 1 | $28 |
| Rxsight Inc | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Harrow Eye, LLC | 1 | $21 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$369
- Kahook Dual Blade$174
- Streamline Surgical System$174
- Ahmed Glaucoma Valve$174
- iStent inject W$150
- Clareon PanOptix Pro$147
- Clareon$147
- iDose$146
- XEN$142
- Hydrus$135
- Tecnis IOL$132
- LenSx$130
- iStent Trabecular Micro-Bypass Stent System$125
- iStent inject Trabecular Micro-Bypass Stent System$125
- LUMIGAN$125
- DURYSTA$125
- Rhopressa$122
- Rocklatan$122
- Centurion$114
How this compares
$4,917 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 111 | $69,551 |
| RhopressaNetarsudil Mesylate | 122 | $61,447 |
| RocklatanNetarsudil Mesylat/Latanoprost | 53 | $32,126 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $19,989 |
| Prednisolone Acetate | 435 | $19,489 |
| Latanoprost | 819 | $11,085 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $8,139 |
| Cyclosporine | 15 | $8,084 |
| VyzultaLatanoprostene Bunod | 15 | $7,908 |
| MoxifloxacinMoxifloxacin Hcl | 325 | $7,803 |
| Travoprost | 55 | $7,777 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 444 | $7,288 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $7,030 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 26 | $6,362 |
| Alphagan PBrimonidine Tartrate | 14 | $6,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $812 | $95,870172 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $172 | $93,573175 claims |
| AlconSimbrinza | $1,256 | $8,13929 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $18 | $7,90815 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $32 | $4,15012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Medina
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- David RogersColumbus$1.5M
- Michael SnyderCincinnati$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.